Use and Pitfalls of NITs in Patients with Diabetes - Alina Allen, MD

Innovations in NAFLD Care Workshop 2023

101 Biomarker in Fibrotic Liver Disease OR the Armamentarium of Non-invasive Test to Stage Liver Disease -Jörn Schattenberg, MD

Innovations in NAFLD Care Workshop 2023

Medical Therapy in the Near Future - Stephen Harrison, MD, FACP, FAASLD

Innovations in NAFLD Care Workshop 2023

Time Restricted Feeding for the Management of Non-Alcoholic Fatty Liver Disease: Interim Analysis from a Randomized, Placebo-Controlled Interventional Study - Angelo Armandi

Innovations in NAFLD Care Workshop 2023

A Global Survey of Health Care Workers Awareness Of Non-alcoholic Fatty Liver Disease - Stan Driessen

Innovations in NAFLD Care Workshop 2023

Social Jetlag and Mediterranean Diet Adherence are Associated with Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease - Gabriele Castelnuovo

Innovations in NAFLD Care Workshop 2023

Establishing a Clinical Research Network for a Platform Trial in Non-alcoholic Steatohepatitis - Elena Sena

Innovations in NAFLD Care Workshop 2023

Prevalence of Liver Fibrosis and Cirrhosis in the German Disease Management Program for Type 2 Diabetes - Dr. Maurice Michel | Abstract Oral Presentation #6 video

Innovations in NAFLD Care Workshop 2023

John Odero Ong’ech, MB.Ch.B, M.Med. Obs. / Gynae. MPH, FCOG(ECSA)

Behavioral Interventions - A.G (Onno) Holleboom, MD, PhD slidesets

Innovations in NAFLD Care Workshop 2023